Dr. Arzu Selen joins FDA's Office of New Drug Quality Assessment (Rockville, MD, www.fda.gov/cder) as the associate director for biopharmaceutics.
Dr. Arzu Selen joins FDA’s Office of New Drug Quality Assessment (Rockville, MD, www.fda.gov/cder) as the associate director for biopharmaceutics. Since joining FDA in 1997, Selen has been in the office of clinical pharmacology and has been actively involved in several FDA initiatives related to pediatrics.
Dr. Julie Beitz has been appointed as the director for the Office of Drug Evaluation III (Rockville, MD, www.fda.gov/cder). Beitz has had a 12-year career at FDA involving both pre- and post-approval regulatory activities. Since January 2006, she has served as the acting director of the Office of Drug Evaluation III.
